Presented in part at the 16th Annual Multidisciplinary Symposium on Breast Disease, February 10-13, 2011.
Pathologic Tumor Response of Invasive Lobular Carcinoma to Neo-adjuvant Chemotherapy
Article first published online: 4 OCT 2012
© 2012 Wiley Periodicals, Inc.
The Breast Journal
Volume 18, Issue 6, pages 569–574, November/December 2012
How to Cite
Joh, J. E., Esposito, N. N., Kiluk, J. V., Laronga, C., Khakpour, N., Soliman, H. and Catherine Lee, M. (2012), Pathologic Tumor Response of Invasive Lobular Carcinoma to Neo-adjuvant Chemotherapy. The Breast Journal, 18: 569–574. doi: 10.1111/tbj.12006
Supported in part by the Don and Erika Wallace Breast Cancer Foundation (MCL).
- Issue published online: 5 NOV 2012
- Article first published online: 4 OCT 2012
- breast cancer;
- invasive lobular carcinoma;
- neo-adjuvant chemotherapy;
- tumor response
Abstract: Neo-adjuvant chemotherapy is used for locally advanced breast cancer patients with significant variation in tumor response. Our objective is to determine the clinicopathologic effect of neo-adjuvant chemotherapy on invasive lobular carcinoma. A review of a single-institution data base of women diagnosed with breast cancer identified 30 patients from 1999 to 2009 with operable invasive lobular carcinoma who received neo-adjuvant chemotherapy. Patient demographics and clinicopathologic data were reviewed. Cases were reviewed by a single pathologist (NNE). Residual cancer burden class was determined for each case. Median patient age was 50 years (range 25–79). All tumors were hormone receptor positive and clinical stage II or III carcinomas. Most patients (53.3%) had combination anthracycline- and taxane-based chemotherapy. Therapy-related changes were noted within the tumor bed in 25 (83.3%) patients. Six (30%) of 20 patients with residual axillary disease had therapy-related nodal changes. There were 11 patients with moderate residual disease (class II) and 18 (60%) with extensive (class III); there were no complete pathologic responses (class 0). Only one patient (3.3%) converted from mastectomy to breast-conserving surgery. Four (13.3%) patients developed distant metastases; all had pleomorphic-type, clinical stage III tumors with residual cancer burden III classification and developed distant disease in the 2 years after surgery (range 0–26 months). Median follow-up time was 29.5 months (range 7–132). Patients with locally advanced pleomorphic-type lobular carcinoma appear to develop early post-treatment metastatic disease. Neo-adjuvant chemotherapy did not appear to have significant impact on the surgical treatment of patients with invasive lobular carcinoma.